FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048509056> ?p ?o ?g. }

• W3048509056 endingPage "1329" @default.
• W3048509056 startingPage "1321" @default.
• W3048509056 abstract "Background Patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have limited treatment options and poor prognoses. Tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy has shown early promise in improving survival outcomes, but at a high upfront cost. This study evaluated the cost-effectiveness of tisagenlecleucel versus salvage chemotherapy for treating patients with r/r DLBCL who have failed at least 2 lines of systemic therapies.Methods A hybrid decision tree and three-state partitioned survival model (progression-free (PF), progressive disease and death) was developed from the Singapore healthcare payer perspective. Survival curves from JULIET trial and CORAL-1 extension study were extrapolated beyond trial period over a 15-year time horizon to estimate the underlying progression-free survival and overall survival parametric distributions for both arms. Health state utilities were retrieved from the literature, and direct costs were sourced from public healthcare institutions in Singapore. One-way probabilistic sensitivity analyses and scenario analyses were conducted to explore the impact of uncertainties and assumptions on cost-effectiveness results.Results Compared with salvage chemotherapy, tisagenlecleucel was associated with a base-case incremental cost-effectiveness ratio (ICER) US$508,530 (S$686,516) per quality adjusted life year (QALY) gained and US$320,200 (S$432,269) per life year (LY) gained. One-way sensitivity analysis showed the ICER was most sensitive to time horizon, PF utility and cost of tisagenlecleucel. Scenario analyses confirmed that the ICERs remained high under favorable assumptions and substantial price reduction was required to reduce the ICER.Conclusions Our analysis showed tisagenlecleucel use in r/r DLBCL patients who failed at least 2 prior lines of systemic therapies was associated with exceedingly high ICER, which is unlikely to represent good use of healthcare resources. Comparative clinical evidence from the ongoing trials might provide more insight into future evaluations." @default.
• W3048509056 created "2020-08-18" @default.
• W3048509056 creator A5004172745 @default.
• W3048509056 creator A5004256298 @default.
• W3048509056 creator A5006387249 @default.
• W3048509056 creator A5007239888 @default.
• W3048509056 creator A5008909013 @default.
• W3048509056 creator A5044436762 @default.
• W3048509056 creator A5069229172 @default.
• W3048509056 date "2020-08-25" @default.
• W3048509056 modified "2023-10-14" @default.
• W3048509056 title "Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective" @default.
• W3048509056 cites W1494281429 @default.
• W3048509056 cites W1909881665 @default.
• W3048509056 cites W1969461242 @default.
• W3048509056 cites W1982967337 @default.
• W3048509056 cites W2018071905 @default.
• W3048509056 cites W2144685190 @default.
• W3048509056 cites W2150587745 @default.
• W3048509056 cites W2305142474 @default.
• W3048509056 cites W2744261860 @default.
• W3048509056 cites W2775369717 @default.
• W3048509056 cites W2811188390 @default.
• W3048509056 cites W2889989292 @default.
• W3048509056 cites W2893050608 @default.
• W3048509056 cites W2903062212 @default.
• W3048509056 cites W2905737576 @default.
• W3048509056 cites W2911431721 @default.
• W3048509056 cites W2919051790 @default.
• W3048509056 cites W2920602503 @default.
• W3048509056 cites W2948047060 @default.
• W3048509056 cites W2961991958 @default.
• W3048509056 cites W2991246146 @default.
• W3048509056 cites W3007507981 @default.
• W3048509056 doi "https://doi.org/10.1080/13696998.2020.1808981" @default.
• W3048509056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32780608" @default.
• W3048509056 hasPublicationYear "2020" @default.
• W3048509056 type Work @default.
• W3048509056 sameAs 3048509056 @default.
• W3048509056 citedByCount "17" @default.
• W3048509056 countsByYear W30485090562020 @default.
• W3048509056 countsByYear W30485090562021 @default.
• W3048509056 countsByYear W30485090562022 @default.
• W3048509056 countsByYear W30485090562023 @default.
• W3048509056 crossrefType "journal-article" @default.
• W3048509056 hasAuthorship W3048509056A5004172745 @default.
• W3048509056 hasAuthorship W3048509056A5004256298 @default.
• W3048509056 hasAuthorship W3048509056A5006387249 @default.
• W3048509056 hasAuthorship W3048509056A5007239888 @default.
• W3048509056 hasAuthorship W3048509056A5008909013 @default.
• W3048509056 hasAuthorship W3048509056A5044436762 @default.
• W3048509056 hasAuthorship W3048509056A5069229172 @default.
• W3048509056 hasBestOaLocation W30485090561 @default.
• W3048509056 hasConcept C10515644 @default.
• W3048509056 hasConcept C112930515 @default.
• W3048509056 hasConcept C126322002 @default.
• W3048509056 hasConcept C143998085 @default.
• W3048509056 hasConcept C2776694085 @default.
• W3048509056 hasConcept C2780775027 @default.
• W3048509056 hasConcept C3019080777 @default.
• W3048509056 hasConcept C515549039 @default.
• W3048509056 hasConcept C535046627 @default.
• W3048509056 hasConcept C71924100 @default.
• W3048509056 hasConceptScore W3048509056C10515644 @default.
• W3048509056 hasConceptScore W3048509056C112930515 @default.
• W3048509056 hasConceptScore W3048509056C126322002 @default.
• W3048509056 hasConceptScore W3048509056C143998085 @default.
• W3048509056 hasConceptScore W3048509056C2776694085 @default.
• W3048509056 hasConceptScore W3048509056C2780775027 @default.
• W3048509056 hasConceptScore W3048509056C3019080777 @default.
• W3048509056 hasConceptScore W3048509056C515549039 @default.
• W3048509056 hasConceptScore W3048509056C535046627 @default.
• W3048509056 hasConceptScore W3048509056C71924100 @default.
• W3048509056 hasIssue "11" @default.
• W3048509056 hasLocation W30485090561 @default.
• W3048509056 hasLocation W30485090562 @default.
• W3048509056 hasOpenAccess W3048509056 @default.
• W3048509056 hasPrimaryLocation W30485090561 @default.
• W3048509056 hasRelatedWork W1973891791 @default.
• W3048509056 hasRelatedWork W2006432950 @default.
• W3048509056 hasRelatedWork W2043047856 @default.
• W3048509056 hasRelatedWork W2087322859 @default.
• W3048509056 hasRelatedWork W2152790517 @default.
• W3048509056 hasRelatedWork W2361700749 @default.
• W3048509056 hasRelatedWork W2381345080 @default.
• W3048509056 hasRelatedWork W2600735778 @default.
• W3048509056 hasRelatedWork W4205703606 @default.
• W3048509056 hasRelatedWork W4220877252 @default.
• W3048509056 hasVolume "23" @default.
• W3048509056 isParatext "false" @default.
• W3048509056 isRetracted "false" @default.
• W3048509056 magId "3048509056" @default.
• W3048509056 workType "article" @default.